{
  "nctId": "NCT04198805",
  "briefTitle": "Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)",
  "officialTitle": "The Effect of Vitamin E and Docosahexaenoic Acid Ethyl Ester on Non-Alcoholic Fatty Liver Disease (NAFLD) - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)",
  "protocolDocument": {
    "nctId": "NCT04198805",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2021-05-10",
    "uploadDate": "2023-03-10T11:26",
    "size": 1283151,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04198805/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 205,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-01-03",
    "completionDate": "2022-09-01",
    "primaryCompletionDate": "2022-09-01",
    "firstSubmitDate": "2019-10-30",
    "firstPostDate": "2019-12-13"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Male or female gender\n* ≥18 years of age\n* A new diagnosis or reconfirmation of previously known fatty liver by imaging (ultrasound or CT or MRI), or by liver biopsy within ≤ 4 years\n* Fibroscan CAP score \\>300db\n* Hepatic fat fraction ≥12% by MRI PDFF\n* ALT≥ 40 U/L\n* eGFR/Creatinine Clearance ≥ 60ml/min\n* Participants with previously diagnosed Type 2 diabetes (up to 50% of sample): they must either be taking anti-diabetic medications, or their fasting (\\>10 hours) glucose must be ≥ 100 mg/dL at the time of screening\n* Stable weight (±5%) for at least 3 months\n* Subjects willing and able to give written informed consent and to understand, to participant and to comply with the clinical study requirements.\n\nExclusion Criteria:\n\n* Evidence of alternative causes of hepatic steatosis or other forms of chronic liver disease, e.g. Hep.B, Hep.C\n* Evidence of acute Hepatitis A\n* Serum ALT or AST ≥ 250 U/L\n* Serum Alkaline Phosphatase \\> 2 ULN\n* Total bilirubin \\> 2 ULN in the absence of Gilbert's Syndrome \\[In patients with Gilbert's Syndrome, direct bilirubin must not exceed 2 ULN\\]\n* HbA1c≥9.5%\n* Decompensated acute or chronic liver disease\n* Clinical, imaging or histological evidence of cirrhosis\n* Use of anti-NASH drugs (e.g. thiazolidinediones) in the 3 months prior to randomization\n* Use of a non-stable dose of statins or fibrates in the 3 months prior to randomization\n* Use of fish oil, algal oil or Krill oil supplements, drugs or foods fortified with omega-3s in the 2 months prior to randomization (\\>200mg DHA/d and/or \\>60mg EPA/d by FFQ)\n* Known intolerance to vitamin E or DHA\n* Malabsorption of Vit E (e.g. due to steatorrhea, chronic pancreatitis, severe cholestasis)\n* Vitamin E supplementation of greater than 100 IU/day in the 3 months prior to randomization\n* History of bariatric surgery (jejunoileal bypass or gastric weight loss surgery) or currently undergoing evaluation for bariatric surgery\n* History of biliary diversion\n* Known positivity for antibody to Human Immunodeficiency Virus (HIV)\n* Patients with coagulopathy (PT ≥3 sec.from ULN), thrombocytopenia (\\<70K)\n* Contraindication to MRI (implants, metal…)\n* Active, serious medical disease or disease diagnosis of a life-expectancy less than 5 years\n* Ongoing or recent alcohol consumption \\> 21 drinks (1 drink= 12 oz regular beer, or 5 oz wine, or 1.5 oz distilled spirits) per week in men and \\> 14 drinks per week in women as per subject self-report as part of medical history.\n* Active substance abuse, such as oral, inhaled or injected illicit drugs (except marijuana), in the year prior to screening\n* Women of childbearing potential: positive pregnancy test during screening or at randomization or unwillingness to use an effective form of birth control during the trial\n* Women who are breastfeeding\n* Any other condition which, in the opinion of the investigator would impede compliance or hinder completion of the study\n* Subjects who are enrolled in an interventional clinical study or have received an investigational new drug or product within the last 30 days prior to screening\n* Participants diagnosed with type 1 diabetes",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in Hepatic Fat Fraction [%] Between of Vitamin E and DHA EE vs Placebo",
        "description": "A change in liver fat content relative to baseline between Vitamin E and DHA EE vs placebo. This will be measured by MRI-PDFF at baseline and after 6 months of intervention (value at 6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Hepatic Fat Fraction [%] Between Vitamin E vs Placebo Arm",
        "description": "Change in liver fat content relative to baseline between Vitamin E vs placebo arm. This will be measured by MRI-PDFF at baseline and after 6 months of intervention (value at 6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Hepatic Fat Fraction [%] Between DHA EE vs Placebo Arm",
        "description": "Change in liver fat content relative to baseline between DHA EE vs placebo arm. This will be measured by MRI-PDFF at baseline and after 6 months of intervention (value at 6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change After 6 Months of DHA EE and/ or Vitamin E Intervention in the Anthropometric Measure, Waist Circumference.",
        "description": "Evaluation of baseline and 6 month measurements of waist circumference in the DHA EE and /or Vitamin E intervention over a 6 month period.",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change After 6 Months of DHA EE and /or Vitamin E Intervention in the Anthropometric Measure, Bodyweight.",
        "description": "Evaluation of baseline and 6-month measurements of body weight in the DHA EE and /or Vitamin E intervention over a 6 month period.",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change After 6 Months of DHA EE and/ or Vitamin E Intervention in the Anthropometric Measure, Waist-to-hip Ratio .",
        "description": "Evaluation of baseline and 6-month measurements of waist-to-hip ratio (the circumference of the waist divided by the circumference of the hips) in the DHA EE and /or Vitamin E intervention over a 6 month period.",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change After 6 Months of DHA EE and/ or Vitamin E Intervention in the Anthropometric Measure, Body Mass Index (BMI)",
        "description": "Evaluation of baseline and 6-month measurements of body mass index (BMI) in the DHA EE and /or Vitamin E intervention over a 6 month period.",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Insulin Levels to Determine Insulin Resistance",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Liver Enzymes (ALT) in the DHA EE and /or Vitamin E Intervention Over a 6 Month Period.",
        "description": "Evaluation of baseline and 6-month liver enzymes: alanine transaminase (ALT) in the DHA EE and /or Vitamin E intervention over a 6 month period value at (6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Liver Enzymes (AST) in the DHA EE and /or Vitamin E Intervention Over a 6 Month Period.",
        "description": "Evaluation of baseline and 6-month liver enzymes: aspartate aminotransferase (AST) in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Liver Enzymes Bilirubin in the DHA EE and /or Vitamin E Intervention Over a 6 Month Period.",
        "description": "Evaluation of baseline and 6-month liver enzymes: Bilirubin in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Liver Enzymes Alkaline Phosphatase in the DHA EE and /or Vitamin E Intervention Over a 6 Month Period.",
        "description": "Evaluation of baseline and 6-month liver enzymes: Alkaline Phosphatase in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Fibrosis-4 (FIB-4) Score",
        "description": "The formula for FIB-4 is: Age (\\[yr\\] x AST \\[U/L\\]) / ((PLT \\[10(9)/L\\]) x (ALT \\[U/L\\])(1/2)). A value of FIB-4 below 1.30 is considered as low risk for advanced fibrosis; a value of FIB-4 over 2.67 is considered as high risk for advanced fibrosis",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Plasma Vitamin E Concentration",
        "description": "Evaluation of baseline and 6-month plasma Vitamin E concentration in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Plasma DHA EE Concentration",
        "description": "Evaluation of baseline and 6-month plasma DHA EE concentration in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Lipid Profile (HDL-C)",
        "description": "Evaluation of baseline and 6-month lipid profile (HDL-C) in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Lipid Profile (Low Density Lipoprotein (LDL-C))",
        "description": "Evaluation of baseline and 6-month lipid profile (low density lipoprotein (LDL-C))in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Lipid Profile (Triglycerides)",
        "description": "Evaluation of baseline and 6-month lipid profile (TGs)in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Lipid Profile (Oxidized LDL)",
        "description": "Evaluation of baseline and 6-month lipid profile (oxidized LDL) in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Health Related Quality of Life Score (Short Form (SF-36))",
        "description": "Evaluation of baseline and 6-month quality of life score (SF-36) in the DHA EE and /or Vitamin E intervention over a 6 month period (value at 6 months minus value at baseline). The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Dietary Intake Levels of Long-chain Polyunsaturated Fatty Acids (LC-PUFA ) (i.e. DHA and EPA) as Measured by the Food Frequency Questionnaire (FFQ)",
        "description": "Evaluation of baseline and 6-month dietary intake levels of LC-PUFA (i.e. DHA and EPA) as measured by the Food Frequency Questionnaire (FFQ)in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Inflammatory Markers (Cytokeratin 18 (CK-18))",
        "description": "Evaluation of baseline and 6-month inflammatory markers (cytokeratin 18) in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Inflammatory Markers (IL-1β)",
        "description": "Evaluation of baseline and 6-month inflammatory markers (IL-1β) in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      },
      {
        "measure": "Change in Inflammatory Markers (TNFα)",
        "description": "Evaluation of baseline and 6-month inflammatory markers (TNFα) in the DHA EE and /or Vitamin E intervention over a 6 month period (6 months minus value at baseline).",
        "timeFrame": "Baseline to 6 months"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 23,
      "otherCount": 0,
      "totalCount": 24
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:12.158Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}